$CLR stock update

CLR slipped below 50 day average due to falling oil prices and disappointing earnings. On 8/5 Q2 earnings were released and the stock fell short. I still recommend holding as the energy sector is down as a whole.

$MO update

There was a slight dip over last month but the stock is still up 10% this year and only 3% below its yearly high. It has also been given a 5 year earnings stability factor of 1 (0-99). In recent news, 29 states are seeking tighter e-cig regulations from the FDA. Restrictions would include selling …

$MO update Read More »

$MO update

Altria (MO) is a long term investment for the Club as it yields a high divident and long term growth. Over the past 44 years, MO has increased it’s dividents every year. It currently yields %5.2 and a high payout ratio…just a reminder of why we hold on to this stock.

$BTI update

BTI has benefited from recent talks of axquisitions amount tobacco companies. Recently there have been talks of a Loullard/Reynolds Meyer merger. Additional, BTI could take over or have a joint venture with Reynolds American (RAI). BTI already has 42% stock in RAI and the takeover would expand its footprint in the US, making it Altria’s …

$BTI update Read More »

$MO for September

Will E-Cigs effect big tobacco? E-cigarettes are changing the way people consume tobacco and, overall, offer a much bigger savings than traditional cigarettes. Goldman Sachs provided that e-cigs will account for 10 billion in retail sails over the next few years, which amounts to approximately 10% of total tobacco sales. Altria has chosen not to …

$MO for September Read More »

$OMER update

Omeros has rebounded in the past few months and is currently at $5.41. The rise is due to the approval of preconditions for OMS302. This stock fluctuates with market approval and drug testing but I recommend holding this stock.

$MO update

Altria is at $36.27. This stock maintains a high divident payer and has consistent earnings. Cigarette volumes still tend to be flat but smokeless tobacco and wine volumes continue to increase. This stock is steady and I recommend the Club hold.

$OMER update

In recent news, OMER presented at the 2013 Future Leaders in Biotech Industry in 04/2013. This stock has dropped below $4.00 this month. This stock is looking less like an opportunity. Important drugs are awaiting FDA approval, but I am not seeing enough supporting data that, even with new approvals, we will see a market …

$OMER update Read More »


Altria’s current share price is $35.48, close to it’s 52 week high of $36.29. Altria has outperformed the S&P by 60%. This company continues to show a strong balance sheet. As this company shares a major portion of its profits to shareholders and continues to diversify in new markets (smokeless products, cigars, wines etc.) I …

$MO Read More »